Rodriguez-Meira, Alba http://orcid.org/0000-0001-9630-6968
Norfo, Ruggiero
Wen, Sean
Chédeville, Agathe L.
Rahman, Haseeb
O’Sullivan, Jennifer
Wang, Guanlin
Louka, Eleni http://orcid.org/0000-0002-0543-7397
Kretzschmar, Warren W.
Paterson, Aimee
Brierley, Charlotte
Martin, Jean-Edouard
Demeule, Caroline
Bashton, Matthew http://orcid.org/0000-0002-6847-1525
Sousos, Nikolaos http://orcid.org/0000-0002-9100-2954
Moralli, Daniela
Subha Meem, Lamia
Carrelha, Joana
Wu, Bishan
Hamblin, Angela
Guermouche, Helene http://orcid.org/0000-0003-4074-1623
Pasquier, Florence
Marzac, Christophe
Girodon, François http://orcid.org/0000-0003-3151-1068
Vainchenker, William http://orcid.org/0000-0003-4705-202X
Drummond, Mark
Harrison, Claire
Chapman, J. Ross http://orcid.org/0000-0002-6477-4254
Plo, Isabelle
Jacobsen, Sten Eirik W. http://orcid.org/0000-0002-1362-3659
Psaila, Bethan http://orcid.org/0000-0001-8198-9663
Thongjuea, Supat
Antony-Debré, Iléana http://orcid.org/0000-0002-1911-146X
Mead, Adam J. http://orcid.org/0000-0001-8522-1002
Funding for this research was provided by:
Cancer Research UK (C42639/A26988, C5255/A20936)
RCUK | Medical Research Council (MC_PC_19049, MC_PC_19049)
Wellcome Trust (222800/Z/21/Z)
Emergence Canceropole Ile de France, Association pour la Recherche contre le cancer, Siric-Socrate, INCA-PLBIO
Article History
Received: 18 February 2022
Accepted: 20 July 2023
First Online: 4 September 2023
Competing interests
: A.R.M. and A.J.M. are authors on a patent related to TARGET-seq (US Patent App. 17/038,548). A patent relating to the TARGET-seq technique is licensed to Alethiomics, a spin-out company from the University of Oxford with equity owned by B.P. and A.J.M. and research funding to B.P. and A.J.M. The other authors declare no competing interests.